Chien-Fu Hung

Author PubWeight™ 119.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003 1.71
2 Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol 2003 1.68
3 Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004 1.66
4 A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005 1.61
5 Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003 1.56
6 Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines 2007 1.50
7 Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007 1.43
8 Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007 1.39
9 Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009 1.38
10 Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005 1.32
11 Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2004 1.30
12 Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008 1.29
13 Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 2013 1.27
14 Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004 1.24
15 Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther 2007 1.23
16 Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis. BMC Gastroenterol 2006 1.23
17 Activation of Akt as a mechanism for tumor immune evasion. Mol Ther 2008 1.22
18 Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003 1.21
19 Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005 1.19
20 Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs 2010 1.18
21 Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 2002 1.17
22 Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2007 1.12
23 Therapeutic HPV DNA vaccines. Immunol Res 2010 1.12
24 DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci 2011 1.11
25 Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 2012 1.10
26 Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine 2007 1.07
27 Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) 2008 1.04
28 Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2008 1.04
29 Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 2004 1.03
30 Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun 2008 1.02
31 Inactivation of viruses by coherent excitations with a low power visible femtosecond laser. Virol J 2007 1.02
32 Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther 2010 1.01
33 Endoscopic retrograde cholangiography in the diagnosis and treatment of mucobilia. Scand J Gastroenterol 2008 1.01
34 HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 2007 1.01
35 Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 2005 1.01
36 DNA vaccines for cancer. IDrugs 2003 1.00
37 A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 2006 1.00
38 Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res 2010 0.99
39 Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010 0.99
40 Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt 2010 0.99
41 Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res 2012 0.99
42 HPV DNA vaccines. Front Biosci 2003 0.98
43 Inactivation of viruses by laser-driven coherent excitations via impulsive stimulated Raman scattering process. J Biomed Opt 2007 0.98
44 In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination. Cell Biosci 2011 0.97
45 Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther 2009 0.97
46 Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012 0.96
47 Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther 2011 0.96
48 Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater 2013 0.95
49 Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine 2011 0.95
50 Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci 2005 0.95
51 Intrahepatic sarcomatoid cholangiocarcinoma: clinical analysis of seven cases during a 15-year period. Chang Gung Med J 2009 0.95
52 Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol 2009 0.94
53 Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine 2008 0.94
54 Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother 2013 0.94
55 Immune mechanism of the antitumor effects generated by bortezomib. J Immunol 2012 0.93
56 Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer 2007 0.93
57 Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 2013 0.92
58 Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008 0.92
59 Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther 2009 0.91
60 Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects. PLoS One 2012 0.91
61 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008 0.90
62 Therapeutic HPV DNA vaccines. Expert Rev Vaccines 2009 0.90
63 Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res 2014 0.89
64 Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 2004 0.89
65 Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci 2010 0.89
66 Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther 2003 0.89
67 A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. Int J Cancer 2013 0.88
68 Combination of viral oncolysis and tumor-specific immunity to control established tumors. Clin Cancer Res 2009 0.88
69 DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine 2010 0.88
70 Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci 2009 0.88
71 Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. Hum Gene Ther 2007 0.87
72 DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett 2007 0.87
73 Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer 2007 0.87
74 DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother 2014 0.87
75 Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70. Cancer Res 2007 0.87
76 DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen. Hum Gene Ther 2005 0.86
77 Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen. Cell Biosci 2012 0.86
78 Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 2009 0.86
79 RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther 2008 0.86
80 Critical illness-related corticosteroid insufficiency in patients with severe acute biliary pancreatitis: a prospective cohort study. Crit Care 2009 0.86
81 Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine 2004 0.85
82 Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol 2008 0.85
83 Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol Lett 2006 0.85
84 Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing. Mol Ther 2012 0.85
85 Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci 2010 0.85
86 Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J Biomed Sci 2011 0.84
87 A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. J Biomed Sci 2004 0.84
88 Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 2002 0.84
89 Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. J Biomed Sci 2010 0.83
90 HPV pseudovirions as DNA delivery vehicles. Ther Deliv 2011 0.83
91 LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines. Vaccine 2011 0.83
92 Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans. J Immunol 2008 0.83
93 Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine 2010 0.82
94 Uterine artery embolization for symptomatic uterine leiomyoma and adenomyosis. J Formos Med Assoc 2003 0.82
95 alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine 2008 0.82
96 Immunotherapeutic strategies employing RNA interference technology for the control of cancers. J Biomed Sci 2006 0.82
97 Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. Laryngoscope 2010 0.81
98 Preventive and therapeutic HPV vaccines. Curr Opin Investig Drugs 2007 0.81
99 Regulatory T cells: potential target in anticancer immunotherapy. Taiwan J Obstet Gynecol 2007 0.81
100 Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide. Cell Biosci 2013 0.81
101 Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. PLoS One 2013 0.80
102 Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine 2010 0.80
103 Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model. Immunobiology 2012 0.80
104 Aggressive multimodality treatment for intra-hepatic recurrence of hepatocellular carcinoma following hepatic resection. Chang Gung Med J 2005 0.80
105 Innovative DNA vaccine to break immune tolerance against tumor self-antigen. Hum Gene Ther 2013 0.80
106 Serum levels of apolipoprotein A-I and high-density lipoprotein can predict organ failure in acute pancreatitis. Crit Care 2015 0.79
107 Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency. J Virol 2009 0.79
108 Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS One 2012 0.79
109 Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J Mol Med (Berl) 2013 0.79
110 Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. Cancer Immunol Immunother 2011 0.79
111 Poorly expandable common bile duct with stones on endoscopic retrograde cholangiography. World J Gastroenterol 2012 0.79
112 Differential expression of epidermal growth factor receptor in juvenile and adult-onset recurrent respiratory papillomatosis. Histopathology 2010 0.78
113 Diagnosis and staging of gallbladder carcinoma. Evaluation with dynamic MR imaging. Clin Imaging 2002 0.78
114 Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. Eur J Immunol 2004 0.78
115 Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. BMC Cancer 2011 0.78
116 Femtosecond laser treatment enhances DNA transfection efficiency in vivo. J Biomed Sci 2009 0.78
117 Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen. Cell Biosci 2013 0.78
118 Safety and efficacy of image-guided percutaneous biopsies in the diagnosis of gastrointestinal stromal tumors. Clin Imaging 2012 0.78
119 Sclerosing hepatocellular carcinoma: clinicopathologic features in seven patients from Taiwan and review of the literature. Hepatogastroenterology 2005 0.78
120 Cancer cells containing nanoscale chemotherapeutic drugs generate antiovarian cancer-specific CD4+ T cells in peritoneal space. J Immunother 2012 0.77
121 Intra-peritoneal hyperthermia combining α-galactosylceramide in the treatment of ovarian cancer. PLoS One 2013 0.77
122 Radiation dose exposure of patients undergoing 320-row cardiac CT for assessing coronary angiography and global left ventricular function. Int J Cardiovasc Imaging 2012 0.76
123 Triphasic dynamic CT findings of 63 hepatic focal nodular hyperplasia in 46 patients: correlation with size and pathological findings. Abdom Imaging 2008 0.76
124 Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin. J Biomed Sci 2005 0.76
125 Vaccines against human papillomavirus. Front Biosci 2007 0.76
126 Immunological research using RNA interference technology. Immunology 2007 0.75
127 Direct peroral cholangioscopy and pancreatoscopy for diagnosis of a pancreatobiliary fistula caused by an intraductal papillary mucinous neoplasm of the pancreas: a case report. Dig Endosc 2011 0.75